	US 12,258,574 B2
	Methods and compositions for transducing lymphocytes and regulating the activity thereof
Gregory Ian Frost, West Palm Beach, FL (US); James Joseph Onuffer, Jr., Alameda, CA (US); Ghiabe H. Guibinga, San Diego, CA (US); Farzad Haerizadeh, San Diego, CA (US); and Anirban Kundu, Grand Cayman (KY)
Assigned to Exuma Biotech Corp., West Palm Beach, FL (US)
Filed by Exuma Biotech Corp., West Palm Beach, FL (US)
Filed on May 23, 2023, as Appl. No. 18/322,531.
Application 18/322,531 is a continuation of application No. 18/301,959, filed on Apr. 17, 2023.
Application 18/301,959 is a continuation of application No. 17/467,425, filed on Sep. 6, 2021, abandoned.
Application 17/467,425 is a continuation of application No. 15/644,778, filed on Jul. 8, 2017, granted, now 11,111,505, issued on Sep. 7, 2021.
Application 15/644,778 is a continuation in part of application No. 15/462,855, filed on Mar. 19, 2017, granted, now 10,596,274, issued on Mar. 24, 2020.
Application 15/644,778 is a continuation in part of application No. PCT/US2017/023112, filed on Mar. 19, 2017.
Claims priority of provisional application 62/467,039, filed on Mar. 3, 2017.
Claims priority of provisional application 62/360,041, filed on Jul. 8, 2016.
Claims priority of provisional application 62/390,093, filed on Mar. 19, 2016.
Prior Publication US 2023/0340536 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/867 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); C12N 15/113 (2010.01); C12N 15/33 (2006.01); C12N 15/48 (2006.01); C12N 15/86 (2006.01); C12N 15/87 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 39/461 (2023.05); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464499 (2023.05); A61K 39/464838 (2023.05); C07K 14/005 (2013.01); C07K 14/5418 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 15/1048 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); A61K 2039/572 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/31 (2013.01); C07K 2319/32 (2013.01); C07K 2319/33 (2013.01); C12N 2310/12 (2013.01); C12N 2310/121 (2013.01); C12N 2310/141 (2013.01); C12N 2310/16 (2013.01); C12N 2310/531 (2013.01); C12N 2510/00 (2013.01); C12N 2740/10043 (2013.01); C12N 2740/10045 (2013.01); C12N 2740/10052 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16052 (2013.01); C12N 2760/18422 (2013.01); C12N 2800/30 (2013.01); C12N 2830/002 (2013.01); C12N 2830/008 (2013.01); C12N 2840/203 (2013.01)]

26 Claims

1. A replication incompetent recombinant retroviral particle, comprising:

A. one or more envelope polypeptides;

B. a polynucleotide comprising one or more transcriptional units, wherein each of the one or more transcriptional units is operatively linked to a promoter active in T cells, and wherein the one or more transcriptional units encode:

i. a first engineered signaling polypeptide comprising a lymphoproliferative element wherein the lymphoproliferative element comprises a cytokine receptor polypeptide comprising a signaling domain that is capable of activating a Jak pathway, and promoting proliferation and/or survival of T cells; and

ii. a second engineered signaling polypeptide comprising an antigen specific targeting region (ASTR), a transmembrane domain, and an intracellular activating domain; and

C. an activation element on the surface of the replication incompetent recombinant retroviral particle, wherein the activation element is fused to a heterologous membrane attachment sequence, and wherein the activation element comprises a means for binding to CD3.